Skip to content

Biohaven BHVN Debt-to-assets

Debt-to-assets at other companies

Eli Lilly logo
Eli LillyLLY
0.4×-0.1×
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
0.0×
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
0.0×
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
0.1×0.0×
uniQure logo
uniQureQURE
0.1×0.0×
Roivant Sciences logo
Roivant SciencesROIV
0.0×

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.25B-48.1%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Calculated from Biohaven’s reported figures.

Based on the most recent quarter.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's debt-to-assets?
Biohaven (BHVN) reported debt-to-assets of 0.6× in Q1 2026.
How has Biohaven's debt-to-assets changed year-over-year?
Biohaven's debt-to-assets increased by 692.8% year-over-year, from 0.1× to 0.6×.
What is the long-term trend for Biohaven's debt-to-assets?
Over 4 years (2021 to 2025), Biohaven's debt-to-assets has grown at a 129.3% compound annual growth rate (CAGR), from 0× to 0.6×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.